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Goals: To compare the diagnostic yield and cost-consequences of 2
strategies, screening regardless of symptoms versus case ﬁnding
(CF), using a point-of-care test (POCT), for the detection of celiac
disease (CD) in primary care, to bridge the diagnostic gap of CD in
adults.
Materials and Methods: All subjects under 75 years of age who
consecutively went to their general practitioners’ ofﬁces were
offered POCT for anti-transglutaminase immunoglobulin A anti-
bodies. The POCT was performed on all subjects who agreed, and
then a systematic search for symptoms or conditions associated
with higher risk for CD was performed, immediately after the test
but before knowing the test results. The 2 resulting groups were: (a)
POCT positive and (b) symptomatic subject at CF. Subjects were
deﬁned as symptomatic at CF in the presence of 1 or more symp-
toms. All POCT-positive or symptomatic subjects at CF were
referred to the CD Centers for conﬁrmation of CD. Data on
resource consumption were gathered from patients’ charts. Cost of
examinations, and diagnostic and laboratory tests were estimated
with regional outpatient tariffs (Sicily), and a price of €2.5 was used
for each POCT.
Results: Of a total of 2197 subjects who agreed to participate in the
study, 36 (1.6%) and 671 (30.5%) were POCT positive and
symptomatic at CF, respectively. The yield from the screening and
CF was 5 new celiac patients. The total cost and mean cost for each
new CD case were €7497.35 and €1499.47 for the POCT screening
strategy, and €9855.14 and €1971.03 for the CF strategy, respec-
tively. Assuming consecutive use of both strategies, performing
POCT only in symptomatic subjects at CF, the calculated yield
would be 4 new diagnoses with a total cost of €2345.84 and a mean
cost of €586.46 for each newly diagnosed patient. Only 1 patient
was celiac despite a negative POCT.
Conclusions: Testing symptomatic subjects at CF only by POCT
seems the most cost-effective strategy to bridge the diagnostic gap of
adult CD in primary care.
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case ﬁnding
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Celiac disease (CD) is an autoimmune condition resultingfrom an abnormal reaction to dietary gluten leading to
small bowel villous atrophy. It is a lifelong disorder pre-
senting with a variety of gastrointestinal and extraintestinal
symptoms1–3 and affects approximately 1% of the pop-
ulation worldwide.4–8 Owing to the variable manifestations
of CD, clinical suspicion is not obvious, and, as a con-
sequence, this disorder is underdiagnosed, as revealed by
screening studies.3,9 Screen-detected patients, with clinically
silent disease but manifest small intestinal mucosal lesions,
seem to beneﬁt from a gluten-free diet;10,11 therefore, it has
been claimed that CD detected by screening is not clinically
silent but simply unrecognized.12
Many asymptomatic patients are at risk of developing
a number of gluten exposure-related complications, such as
micronutrient malabsorption, that are associated with
osteoporosis and iron-deﬁciency anemia, autoimmune
disorders,13,14 and increased risk for non-Hodgkin
lymphoma.15 As such, the importance of early recognition
of CD has been underlined.
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Although population screening has been suggested as a
possible strategy for detecting undiagnosed CD, many
doubts remain on the usefulness and cost-effectiveness of
such a strategy, primarily because of low compliance to a
gluten-free diet in asymptomatic cases and the difﬁculty of
deﬁning the best age to screen to reduce false-positive and
false-negative results.16,17 An alternative approach is the
case-ﬁnding (CF) strategy in both adult and pediatric pop-
ulations. This approach relies on an active role played by
primary care physicians in selecting the individuals to be
tested for CD, in the presence of conditions known to be
associated with CD.18
One method of increasing detection rates would be to
introduce a quick screening test in the form of a ﬁnger-prick
blood test in subjects suspected of having CD. Rapid methods
of antibody detection at the point-of-care using blood from
ﬁnger pricks19 have recently become available, and point-of-
care detection of immunoglobulin (Ig) A antibodies in CD has
already been validated for clinical CFs in gastroenterology
settings.20,21 An easy to use on-site whole blood self-TG2-based
ﬁngertip point-of-care test (POCT) has been shown to be
effective in CD CF in school children, at a population-based
level and in children with type 1 diabetes.22,23
At present, there are no comparative studies of diag-
nostic accuracy of the CF approach versus screening in the
same population, utilizing POCT, to determine which is the
costliest strategy.
The main aim of this study was to compare diagnostic
yield of a POCT-based screening for CD versus a CF strategy
in the same general population not yet diagnosed as having
CD, in a primary care setting, using conventional serology
and histology as gold standard. In addition, the study evaluated
the cost-consequences of the different screening strategies
according to resource consumption and to the perspective of
the Sicilian Regional Healthcare System.
MATERIALS AND METHODS
Study Design
Observational cross-sectional study.
Setting
Seven Sicilian regional referral centers for diagnosis
and management of CD and a regional research network of
34 general practitioners (GP) with previous experience in
clinical research.
Study Population
A total of 45,921 subjects throughout Sicily in the care
of 34 GPs.
Data Collection
After thorough practical training, each participating
GP proposed the administration of a POCT for CD diag-
nosis to all subjects below 18 and above 75 years of age who
consecutively accessed their ofﬁce from March to April
2014, until they had each enrolled 70 subjects. POCTs were
administered to the subjects only after receiving oral
informed consent in accordance with recommendations
from the local ethics committee at the University Hospital
of Messina, which had approved the study.
Exclusion Criteria
Age below 18 years, subjects already diagnosed with
CD, subjects tested for CD in the last 12 months, patients
with fever or under treatment with immunosuppressive or
corticosteroids drugs.
POCT
The Biocard Celiac Test, AniBiotech, Vantaa, Finland,
was selected as the point-of-care biomarker test for CD
CF.24–27
This rapid whole blood self-TG2-based IgA-class ﬁn-
gertip test uses the patient’s own endogenous TG2 found in
the erythrocytes of a whole blood sample. When the ﬁn-
gertip blood is hemolyzed, the liberated TG2 forms a
complex with circulating autoantibodies, if present in the
same sample. Blood erythrocyte self-TG2-autoantibody
complexes are captured from the hemolyzed sample by
TG2-binding proteins onto a solid phase and the presence of
autoantibodies is measured by labeled antihuman IgA.20
The results of the POCT were evaluated visually on site after
5 minutes, but no later than 10 minutes, according to the
manufacturer’s recommendations. A positive test result
shows 2 lines on the strip within 10 minutes of collection of a
drop of blood from the ﬁnger, while only 1 line appears if
the test is negative. If there is no line, IgA deﬁciency should
be suspected.
CF
Relevant demographic and clinical data of the persons
enrolled in the study were collected using an electronic case
report form. In particular, information on signs, symptoms,
and conditions associated with higher risk for CD was
collected according to an already utilized, published
questionnaire18 (Table 1), and, if present, subjects were
deﬁned as symptomatic at CF. These clinical data were
recorded before performing the POCT; consequently, both
patients and GPs were unaware of POCT results.
Following the study design, all subjects with a positive
or no line POCT, as well as those with a negative POCT but
symptomatic at CF, were offered further investigations at
the referral centers. All centralized laboratory serologic
determinations were made in blinded manner without
knowledge of the on-site ﬁngertip POCT results.
TABLE 1. List of Signs, Symptoms, and Conditions Associated
With Higher Risk for Celiac Disease
Irritable bowel syndrome
Dyspepsia (requiring endoscopy)
Hashimoto thyroiditis, type 1 diabetes or other autoimmune
endocrinopathies
Anemia
Family history of celiac disease
Stomatitis (> 3 episodes/y)
Dermatitis herpetiformis, vitiligo, alopecia, or psoriasis
Weight loss associated with gastrointestinal symptoms
Short stature
Chronic urticaria
Tooth enamel alterations
Infertility or repeated miscarriages (2 or more)
Rheumatic disease
Hypertransaminasemia sine causa
Epilepsy/ataxia
Adapted from Berti et al.18 Adaptations are themselves works protected
by copyright. So in order to publish this adaptation, authorization must be
obtained both from the owner of the copyright in the original work and from
the owner of copyright in the translation or adaptation.
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CD Diagnosis
All POCT positive and no line subjects, and patients
symptomatic at CF were referred to one of the Regional
Referral Centers of the corresponding enrollment area for a
routine CD diagnostic work-up. This was based on detec-
tion of IgA anti-transglutaminase antibodies (tTG IgA) for
POCT-positive subjects and on IgG deamidated gliadin
peptide antibodies (DGP IgG) plus serum total IgA for
subjects with no-line POCT who were suspected of having
IgA deﬁciency. For all subjects with positive serology, a
histologic examination of 4 endoscopic duodenal biopsies,
including a bulb sample, taken by upper gastrointestinal
endoscopy, was carried out.
The biopsy specimens were ﬁxed in formalin, embed-
ded in parafﬁn, cut, stained with hematoxylin-eosin and
scored by pathologists according to the Marsh-Oberhuber
classiﬁcation.28,29 According to current criteria,30 patients
were diagnosed as having CD if they had a positive serum
tTG IgA test result (or DGP IgG for “no line POCT”) that
was associated with a typical celiac enteropathy at the small
bowel biopsy (partial or subtotal villous atrophy with an
increase in the intraepithelial lymphocyte count).
Serum tTG IgA were determined using an enzyme-linked
immunosorbent assay. DGP IgG were assayed with a com-
mercial kit according to manufacturer’s instructions and cut-off.
To deﬁne GP and patient compliance to the study we
evaluated the performed POCT and completed CF reports
by the number of tests assigned. Moreover, to assess con-
ﬁdence in POCT and awareness of CD, the percentage of
positive POCT and symptomatic subjects at CF sent to the
reference center, respectively, was also arbitrarily assessed.
Statistical Analysis
For sample size calculation, we considered the preva-
lence of CD in CF, 1:1073 (0.1%), about10 times lower than
the prevalence expected in the screening, that is 1%, as
primary outcome. Thus, assuming a population prevalence
of 0.1%, according to a previous study,18 an expected
prevalence in the study of about 0.35%, a statistical power of
80% and a 2-sided signiﬁcance level of 0.05, the minimum
number of subjects for adequate study power was 1995
patients. The sample size was increased by a further 220
patients (for a whole sample of 2215 eligible patients) to
factor in potential refusals or drop-outs.
Sensitivities, speciﬁcities, negative predictive values
(NPV), and positive predictive values (PPV) with relative
95% conﬁdence interval (CI), diagnostic accuracy, positive
and negative likelihood ratio (LR) were calculated for the
POCT, utilizing histology as the gold standard and com-
paring it to the tTG.
Cost Analysis
To assess the cost-consequences of the different strat-
egies, data on resource consumption were gathered through
patients’ charts. Costs of examinations, and diagnostic and
laboratory tests were estimated with regional outpatient
tariffs (Sicily) and for each POCT a price of €2.5 was used.
The study was performed from the Sicilian Regional Health
System perspective, therefore, indirect and intangible costs
were not taken into account.
To evaluate the strength of the results, 2 sensitivity
analyses were developed. In the ﬁrst analysis, a cost of
± 10% for POCT was used, whereas in the second, to
compare POCT screening strategy versus CF a cost for each
GP’s visit of €15.31 was added to every patient in the CF.
This cost for an Italian GP’s visit was retrieved from a
previously published study inﬂated to Euro 2016 according
to the Italian National Institute of Statistics.31
RESULTS
Of the 45,921 subjects who are cared for by 34 GPs
(mean age 50.2 ± 19.6 y, 44.9% males), 133 were already
diagnosed with CD (prevalence= 1:345). Of the 2215 eligi-
ble subjects, older than 18, who were consecutively exam-
ined at the GPs’ ofﬁce during the observation period
(average 1 wk), 2197 (99.2%) agreed to participate to the
study, and underwent the POCT for CD (Fig. 1). The mean
age of the population tested was 50.1± 16.7 (range, 18 to
89), and 801 (36.5%) patients referred were male. Of these, 8
(0.36%) showed a positive test and 28 (1.27%) a no line test,
thus requiring further investigation for CD.
Of the 8 subjects with a positive POCT, only 6 com-
pleted the routine diagnostic work-up, which conﬁrmed CD
diagnosis in 3 of them. Two positive POCT subjects (1 of
them CF positive) refused to undergo further investigations.
Among the 28 subjects with no line at POCT, 16 accepted to
undergo further investigations at the referral celiac center,
and in 2 cases serology and histology conﬁrmed the presence
of CD. No case of selective IgA deﬁciency was conﬁrmed.
Of the 2197 who underwent POCT, 671 (30.5%) met
criteria of suspected CD when applying the CF approach.
The distribution of different conditions/symptoms sugges-
tive of CD is shown in Figure 2.
Of the 671 symptomatic subjects at CF, 639 (95.2%)
turned out negative at POCT. Of these, 351 (52.3%) agreed
to undergo tTG IgA determination at the referral celiac
center: 350 were negative and only 1 had positive serological
markers of CD, and histology of duodenal biopsies con-
ﬁrmed the diagnosis of CD.
As can be seen from Table 2, sensitivity of POCT is
75% (95% CI, 30.1-95.4), speciﬁcity is 99.2% (95% CI, 97.5-
99.7), NPV estimated on subjects who agreed to be referred
to the Celiac Center is 99.7% (95% CI, 98.4-99.9), PPV 50%
(95% CI, 18.8-81.2). LR+ and LR− are 88.2% (95% CI,
23.1-280.3) and 0.25% (95% CI, 0.046-0.705), respectively.
Compared with tTG, sensitivity of POCT is 75% (95% CI,
30-95), speciﬁcity 99% (95% CI, 97-99), NPV 100% (95%
CI, 98-100), PPV 38% (95% CI, 14-69).
When the yield of the different strategies was calculated,
that of screening was 5 celiac patients out of a total of 2197
tested subjects (1:439), 4 of whom would anyway have been
recognized by means of CF; the yield of CF was 5 new CD
diagnoses applying this strategy to 371 symptomatic subjects at
CF who accepted to be referred to Centers, one of whom was
missed at screening. By using both strategies the calculated
yield was 6 new diagnoses out of a total of 2197 tested subjects.
In the base case, taking into account a cost of POCT of
€2.5 and the regional tariffs for examinations, diagnostic,
and laboratory tests a total cost for screening strategy with
POCT of €7497.35 and a mean cost for each CD patient of
€1499.47 were estimated. Instead, for CF strategy a total
cost of €9855.14 and a mean cost of €1971.03 per CD
patient were assessed (Table 3).
Considering the protocol with consecutive use of both
strategies, thus performing the POCT only in symptomatic sub-
jects at CF, a total cost of €2345.84 and a mean cost of €586.46
for each newly diagnosed patient can be assumed (Table 3).
In the ﬁrst sensitivity analysis, considering an increase
of +10% of POCT price (€2.75), total cost and the mean cost
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per CD patient were €8046.60 and €1609.32 for the POCT
strategy, and €2438.59 and €609.65 for the combined
strategy, respectively, with no difference in CF. Instead,
considering a reduction of −10% of POCT price (€2.25), the
total cost and the mean cost per CD patient with POCT
strategy were €6948.10 and €1389.62 for POCT strategy,
whereas they were €2253.09 and €563.27 for the combined
strategy, respectively. Also in the ﬁrst sensitivity analysis,
the protocols including POCT were less costly than CF.
Considering the mean CD patient cost, the POCT
strategy is equal to CF with a price per POCT of €3.57,
whereas the combined strategy is equal to CF with a POCT
price of €17.43.
In the second sensitivity analysis, considering an
additional cost of GP visit of €15.31 in Italy, the CF strategy
showed a dramatic increase in both total (€43,491.21 of
which 33,636.07 for GPs’ visits) and mean CD patient cost
(€8698.24).
Finally, we calculated compliance, evaluating the per-
formed POCT, the completed CF reports compared with the
assigned ones, and the percentage of POCT and/or
symptomatic subjects at CF sent to the reference center.
Compliance of physicians and patients to achieve the plan-
ned objectives of the study are shown in Figure 3.
DISCUSSION
We performed CF based on detecting at least 1
symptom or clinical condition recognized as high risk for
CD in previous studies that widely recommended this
strategy as the best approach to increase the number of CD
diagnoses in the community.18,32 In fact, a CF approach can
be a feasible, successful strategy for detecting undiagnosed
CD in general practice, thus reducing the risk of developing
gluten-related complications.
Nevertheless, such a strategy is not likely to sig-
niﬁcantly increase the number of CD diagnoses up to
achieving the expected prevalence of 1% in the general
population, with almost 60% of CD patients still remaining
undiagnosed.33
In contrast, a mass screening program for CD would
have excessive costs. Therefore, in this respect, a quick, low
cost, easy to perform test, carried out at the point-of-care
could be an effective policy.
Our data conﬁrmed that POCT is easy to use in general
practice and is well accepted by patients, as conﬁrmed by the
low rate of refusal in our study.
As regards the effectiveness of the 2 different
screening approaches, it should be noted that only 1 of 351
symptomatic subjects at CF, who had a negative POCT,
was diagnosed with CD. This observation is somewhat
weak as only half of the symptomatic subjects at CF
agreed to continue the study when they turned out neg-
ative at POCT. This low rate of acceptance may be
explained by the reassurance induced by a negative POCT,
which they trusted in. However, according to these data,
we must underline that POCT showed an excellent NPV
(99.2%); this is even more relevant if we consider the set-
tings where the POCT was performed by personnel who
were not completely dedicated to performing diagnostic
Elegible subjects
n= 2215
POCT
n=2197
POCT Positive
n=8
Symptomatic
at case finding
n=6
Celiac center
n=5
CD= 2
Asymptomatic
at case finding
n=2
Celiac center
n=1
CD= 1 
POCT No line
n=28
Symptomatic
at case finding
n=26
Celiac center
n=15
CD= 2 
Asymptomatic
at case finding
n=2
Celiac center
n=1
CD= 0
POCT Negative
n=2161
Symptomatic
at case finding
n=639
Celiac center
n=351
CD= 1 No CD= 350
Asymptomatic
at case finding
n=1522
Stop
Refusal
n= 18
FIGURE 1. Flowchart of study patient enrollment. POCT indicates point-of-care test.
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procedures, such as GPs in their ofﬁce. In this respect, our
study has 2 further limitations that may overestimate the
NPV of POCT in that, even though we assessed symptoms
in all subjects before knowing the result, among subjects
with POCT negative only those with symptoms were invited
to undergo further investigation and those who were positive
at conventional serology underwent intestinal biopsy. This
may introduce a “double standard bias” that might be more
relevant considering that some celiac patients can have neg-
ative serology.34 Ethical reasons considered in the design
study and approved by the ethics committee did not allow to
eliminate this bias. However, in clinical practice, upper
digestive endoscopy with duodenal biopsy should be offered
to a subject with strong suspicion of CD due to gastro-
intestinal symptoms.
The PPV of POCT found in this study was not sat-
isfying (50%), but the very low cost and high NPV of POCT
make it useful and cost-effective for a population study, in
our opinion.
In our study, 16 patients were referred to the Celiac
Center as no line appeared at the POCT thus suggesting IgA
deﬁciency according to the manufacturer’s instructions;
none of them showed IgA deﬁciency but 2 were diagnosed as
suffering from CD as they tested positive for DGP IgG and
showed intestinal villi atrophy at duodenal histology. These
data suggested that “no line POCT” did not indicate an IgA
deﬁciency, but more probably a possible “false negative”
assay for tTG IgA. Furthermore, they underline the use-
fulness of DGP IgG assay in the serologic work-up of the
CD diagnosis, as demonstrated also by another study which
showed that performing serum tTG IgA plus DGP IgG had
a higher diagnostic accuracy than tTG IgA assay alone.35
On this basis, we must underline another limitation of our
study as we did not perform serum DP IgG assay for all the
patients referred to the Celiac Center. Consequently, other
POCT-positive or POCT-negative/symptomatic patients
could have been missed for CD diagnosis. However, in our
study we stressed the estimation of the cost-effectiveness of
the 2 screening strategies; in this respect, to consider a
routine assay of serum DGP IgG would have greatly
increased the costs.
In comparison with results of previous studies of CF18,32
and of population screening,36 it is of note that the prevalence
of CD at the beginning of our study (1:345) was higher than
that reported by Berti et al18 and thus, the difference of
prevalence at the end of the study (1:330) was less remarkable
than that found in another region. This may depend on the
0
50
100
150
200
250
300
FIGURE 2. Distribution of major conditions/symptoms suggestive of celiac disease in case finding positive patients.
TABLE 2. Accuracy of POCT for Celiac Disease Identification
POCT % 95% CI
Sensitivity 75.0 30.1-95.4
Speciﬁcity 99.2 97.5-99.7
Positive predictive value 50.0 18.8-81.2
Negative predictive value 99.7 98.4-99.9
Diagnostic accuracy 98.9 97.7-99.9
LR+ 88.2 23.1-280.3
LR− 0.252 0.046-0.705
CI indicates conﬁdence interval; LR, likelihood ratio; POCT, point-of-
care test.
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different awareness of GPs in our region that explains the
prevalence of celiac patients already known.
In contrast, the prevalence of CD found by means of
the POCT screening in our study (1:439) is higher than that
reported by Corazza et al36 (1:559) on a similar number of
subjects utilizing conventional celiac serology.
When the costs of the 2 different screening strategies
were compared, POCT showed a 24% lower cost than CF.
However, our results suggest that an integrated program,
performing POCT only in symptomatic subjects at CF is
considerably more cost-effective. In fact, this proposed
integrated strategy involves a planned expenditure of
€586.46 for each newly diagnosed patient, thus allowing a
considerable money saving.
Sensitivity analyses have conﬁrmed the results, but
have also shown that the cost of POCT test affects them.
Despite Italian GPs being paid a capitation fee based
on the number of people (adults or children) registered on
TABLE 3. Yield and Direct Costs of POCT Screening Versus a Case Finding Versus Combined Strategy—Base Case Scenario
Patients Test/Visit Test Cost (€) No. Tested Patients (%) Estimated Cost (€)
POCT screening (no. CD diagnosed= 5)
All POCT 2.50 2197 (100.00) 5492.50
Positive POCT tTG IgA 19.00 6 (0.27) 114.00
Gastroenterology visit 20.66 6 (0.27) 123.96
EGD 56.81 5 (0.23) 284.05
Biopsy 99.40 5 (0.23) 497.00
Histologic exam 14.10 5 (0.23) 70.50
No line POCT DGP IgG 10.27 16 (0.73) 164.32
Total IgA 4.99 16 (0.73) 79.84
Gastroenterology visit 20.66 16 (0.73) 330.56
EGD 56.81 2 (0.09) 113.62
Biopsy 99.40 2 (0.09) 198.80
Histologic exam 14.10 2 (0.09) 28.20
Total cost (€) 7497.35
Mean cost for each cd diagnosis (€) 1499.47
Case ﬁnding (no. CD diagnosed= 5)
All GP visit 0.00 2197 (100.00) 0.00
Symptomatic tTG IgA 19.00 371 (16.89) 7049.00
Total IgA 4.99 371 (16.89) 1851.29
Gastroenterology visit 20.66 5 (0.23) 103.30
EGD 56.81 5 (0.23) 284.05
Biopsy 99.40 5 (0.23) 497.00
Histologic exam 14.10 5 (0.23) 70.50
Total cost (€) 9855.14
Mean cost for each CD diagnosis (€) 1971.03
POCT carried out after case ﬁnding search (no. CD diagnosed= 4)
All GP visit 0.00 2197 (100.00) 0.00
Symptomatic POCT 2.50 371 (16.89) 927.50
Positive POCT tTG IgA 19.00 5 (0.23) 95.00
Gastroenterology visit 20.66 5 (0.23) 103.30
EGD 56.81 2 (0.09) 113.62
Biopsy 99.40 2 (0.09) 198.80
Histologic exam 14.10 2 (0.09) 28.20
No line POCT DGP IgG 10.27 15 (0.68) 154.05
Total IgA 4.99 15 (0.68) 74.85
Gastroenterology visit 20.66 15 (0.68) 309.90
EGD 56.81 2 (0.09) 113.62
Biopsy 99.40 2 (0.09) 198.80
Histologic exam 14.10 2 (0.09) 28.20
Total cost (€) 2345.84
Mean cost for each CD diagnosis (€) 586.46
CD indicates celiac disease; DGP IgG, immunoglobulin G deamidated gliadin peptide antibodies; EGD, esophagogastroduodenoscopy; GP, general
practitioner; POCT, point-of-care test; tTG IgA, IgA anti-transglutaminase antibodies.
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FIGURE 3. Compliance of general practitioners and patients to
study design. CD indicates celiac disease; CF, case finding; POCT,
point-of-care test.
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their list, when we considered the cost for a GP visit, as in
countries with a largely fee-for-service system such as
France and Germany37 the health care expenditure for the
CF strategy was dramatically increased.
According to current data, we believe that the inte-
grated diagnostic pathway may be the most cost-effective
one in the search for new celiac patients, but more phar-
maco-economic evidence, such as cost-effectiveness and
cost-utility analyses developed in Italy (with our speciﬁc
national/regional health care settings) are required to better
evaluate this assumption due to a relatively less trans-
ferability of evidence between countries.
In the Maki et al 2003 study,5 it was estimated that
each case was diagnosed at a cost of €1400, whereas in the
Berti et al 2006 experience, the CF approach had a cost of
€923.25 per case.18
Finally, regarding GP and patient compliance to the
study, we found an excellent percentage of tests performed
(94%) by the number of tests assigned. This indicated the
awareness of GPs regarding CD diagnosis, although we
must underline that they had been involved in a thorough
practical training which surely increased attention to CD. In
contrast, only 61% of POCT positives and 55% of the
symptomatic subjects underwent further evaluation for CD
diagnosis. Both these data indicate the need for improved
educational strategies.
In conclusion, we showed that an accurate POCT
may increase the rates of diagnosis of CD if used effec-
tively as part of a CF approach in primary care and can
save money in comparison with a simple CF strategy.
Results to date are encouraging but further research in this
area is required as recently suggested,38 comparing the
cost-effectiveness or cost-utility, in an Italian setting, of
POCT detecting tTG IgA or anti-DGP IgG and their
combination.
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